Last updated: March 26, 2026
What is NDC 72578-0209?
NDC 72578-0209 refers to a specific pharmaceutical product designated by the National Drug Code (NDC). According to available data, this code corresponds to Tucatinib, a tyrosine kinase inhibitor used primarily to treat advanced unresectable or metastatic HER2-positive breast cancer.
Market Overview
Product Approval and Indications
Tucatinib received FDA approval in April 2020 under priority review. The drug is indicated for the treatment of adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Market Size and Demand Drivers
- Prevalence of HER2-positive breast cancer: Approximately 15-20% of breast cancers are HER2-positive.
- Estimated annual new cases (U.S.): About 150,000 breast cancer cases, with roughly 20% HER2-positive.
- Market penetration: Oncology drugs with targeted therapy like Tucatinib tend to attain rapid uptake in approved indications, especially following clinical trial success and guideline endorsements.
Competitive Landscape
| Drug Name |
Mechanism |
Approval Year |
Market Share |
Price Range (per month) |
| Trastuzumab |
Monoclonal antibody |
1998 |
Dominant |
$2,000–$3,000 |
| Pertuzumab |
Monoclonal antibody |
2012 |
Significant |
$3,000–$4,000 |
| T-DM1 (ado-trastuzumab emtansine) |
Antibody-drug conjugate |
2013 |
Growing |
$7,000–$8,000 |
| Tucatinib |
Tyrosine kinase inhibitor |
2020 |
Emerging |
$12,000–$15,000 |
Key Trends Affecting Market
- Clinical Evidence: Trials show Tucatinib improves progression-free survival (PFS) and overall survival (OS), leading to faster adoption.
- Combination Therapies: Often combined with trastuzumab and capecitabine, expanding its use.
- Pricing Constraints: Targeted cancer drugs face resistance pressure; however, innovative therapies often command premium prices.
- Reimbursement Policies: Coverage policies are favorable in major markets, with payers willing to reimburse for breakthrough therapies.
Price Projections
Short-Term (Next 1-2 Years)
| Assumption |
Impact |
Price Range |
| Launch progression and initial uptake |
Prices stabilize at high levels |
$12,000–$15,000/month |
| Pricing negotiations in the U.S. |
Slight downward pressure |
$11,000–$13,000/month |
| Competitive entries or biosimilars |
Possible price erosion |
$10,000–$12,000/month |
Medium to Long-Term (3-5 Years)
| Assumption |
Impact |
Price Range |
| Increased generic or biosimilar competition |
Moderate price reductions, market sharing |
$8,000–$10,000/month |
| Evolving clinical guidelines favoring Tucatinib |
Sustained or increased prices |
$12,000–$15,000/month |
Key Price Drivers
- Patent Status: Tucatinib’s patent protection extends until at least 2030, delaying generic entry.
- Clinical Outcomes: Demonstrated improvements in survival will support premium pricing.
- Market Penetration: Rapid adoption in the metastatic HER2-positive setting influences pricing power.
- Price Sensitivity: Payers and manufacturers balance cost with clinical benefit.
Regulatory and Policy Influences
- FDA: Approves based on clinical benefit; post-approval studies may affect pricing if new indications emerge.
- CMS & Payers: Coverage decisions depend on clinical efficacy and cost-effectiveness metrics.
- Pricing Regulations: International markets face additional price controls, impacting global price trajectories.
Conclusion
NDC 72578-0209 (Tucatinib) is positioned in a growing niche within targeted breast cancer therapy. Its high price point reflects its recent market entry, clinical benefits, and limited competition. Short-term prices remain stable with potential for modest erosion over time due to emerging biosimilar or combination therapy options. Long-term pricing depends on clinical outcomes, market penetration, and regulatory environment.
Key Takeaways
- Tucatinib’s initial market price ranges from $12,000–$15,000/month.
- Market demand is driven primarily by HER2-positive metastatic breast cancer prevalence.
- Competitive pressures and biosimilar entries could reduce prices from current levels.
- Patent protection supports sustained high pricing until mid-decade.
- Clinical trial results favoring survival enhancements support premium pricing strategies.
FAQs
1. What factors most influence Tucatinib’s market price?
Clinical efficacy, patent status, market penetration, and competitive landscape primarily shape pricing.
2. How does Tucatinib compare financially to other HER2-targeted therapies?
It commands a higher monthly price, reflecting recent approval and clinical benefits, but faces competition from older, less expensive options.
3. When are biosimilars or generics expected to impact the price?
Patent expiration around 2030 could lead to biosimilar entry, likely causing price reductions.
4. How do reimbursement policies affect Tucatinib’s pricing?
Reimbursement relies on clinical advantage; favorable policies facilitate maintained or increased pricing.
5. What future market developments could alter current price trends?
New clinical data, expanded indications, competitive biosimilars, and health policy changes can influence future pricing.
References
[1] Food and Drug Administration (FDA). (2020). FDA Approves Tucatinib for Breast Cancer.
[2] IQVIA. (2022). Market Trends for HER2-Targeted Cancer Therapies.
[3] EvaluatePharma. (2022). Global Oncology Drug Pricing and Market Forecasts.
[4] Centers for Medicare & Medicaid Services (CMS). (2021). Coverage Policies for Targeted Oncology Therapies.
